Novel treatment has 97 percent success rate in co-infected patients —
Roughly 20 to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both blood-borne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV. … Read the full story from the UC San Diego News Center
Wyles D.L., Ruane P.J., Sulkowski M.S., et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. New England Journal of Medicine July 21, 2015, 10.1056/NEJMoa1503153. Free full text
A collaborative partnership between the UC San Diego Liver Center and Antiviral Research Center (AVRC) has resulted in 19 clinical trials for hepatitis C virus (HCV), focused on developing more effective and well-tolerated HCV treatments…. Read the full story from the UCSD Newsroom
Dr. Martina Buck, faculty researcher in the Division of Gastroenterology, has developed the first tissue culture system for the Hepatitis C virus. The system offers a model in which investigators can more easily test potential treatments for Hepatitis C.
Her report of the system is published in PLoS ONE.
Citation for the report: Buck M (2008) Direct Infection and Replication of Naturally Occurring Hepatitis C Virus Genotypes 1, 2, 3 and 4 in Normal Human Hepatocyte Cultures. PLoS ONE 3(7): e2660. doi:10.1371/journal.pone.0002660 | Read the report (free full text)